On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review

Anna Bong; Michael Doughty; Norman Button; David  Mansfield

doi:10.1111/cxo.12393

On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review

Anna Bong, Michael Doughty, Norman Button, David Mansfield

Vision Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

The aim was to compare efficacy of treatments for diabetic macular oedema (DMO) from changes in visual acuity (VA) and central macular thickness (CMT). Peer-reviewed articles from 2004 to 2014 reporting intravitreal injections of bevacizumab (IVB), ranibizumab (IVR) or triamcinolone acetonide (IVTA) or laser photocoagulation therapy (LPT) provided data on pre-treatment (baseline) and final outcome measures. Net changes and relative changes (percentage) were assessed by linear regression analyses.

Original language	English
Pages (from-to)	491-497
Number of pages	7
Journal	Clinical and Experimental Optometry
Volume	99
Issue number	6
Early online date	19 Jun 2016
DOIs	https://doi.org/10.1111/cxo.12393
Publication status	Published - Nov 2016

Keywords

anti-VEGF treatments, corticosteroid treatments, diabetic macular oedema, laser photocoagulation

Documents and Links

10.1111/cxo.12393

Fingerprint Dive into the research topics of 'On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review'. Together they form a unique fingerprint.

Cite this

@article{5371427b4c2f4d4bba98497f07590404,

title = "On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review",

abstract = "The aim was to compare efficacy of treatments for diabetic macular oedema (DMO) from changes in visual acuity (VA) and central macular thickness (CMT). Peer-reviewed articles from 2004 to 2014 reporting intravitreal injections of bevacizumab (IVB), ranibizumab (IVR) or triamcinolone acetonide (IVTA) or laser photocoagulation therapy (LPT) provided data on pre-treatment (baseline) and final outcome measures. Net changes and relative changes (percentage) were assessed by linear regression analyses.",

keywords = "anti-VEGF treatments, corticosteroid treatments, diabetic macular oedema, laser photocoagulation",

author = "Anna Bong and Michael Doughty and Norman Button and David Mansfield",

note = "Accepted: 7-1-16 (outwith REF policy scope) Online pub: 19-6-16 Acceptance from VoR",

year = "2016",

month = nov,

doi = "10.1111/cxo.12393",

language = "English",

volume = "99",

pages = "491--497",

journal = "Clinical and Experimental Optometry",

issn = "0816-4622",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review

AU - Bong, Anna

AU - Doughty, Michael

AU - Button, Norman

AU - Mansfield, David

N1 - Accepted: 7-1-16 (outwith REF policy scope) Online pub: 19-6-16 Acceptance from VoR

PY - 2016/11

Y1 - 2016/11

N2 - The aim was to compare efficacy of treatments for diabetic macular oedema (DMO) from changes in visual acuity (VA) and central macular thickness (CMT). Peer-reviewed articles from 2004 to 2014 reporting intravitreal injections of bevacizumab (IVB), ranibizumab (IVR) or triamcinolone acetonide (IVTA) or laser photocoagulation therapy (LPT) provided data on pre-treatment (baseline) and final outcome measures. Net changes and relative changes (percentage) were assessed by linear regression analyses.

AB - The aim was to compare efficacy of treatments for diabetic macular oedema (DMO) from changes in visual acuity (VA) and central macular thickness (CMT). Peer-reviewed articles from 2004 to 2014 reporting intravitreal injections of bevacizumab (IVB), ranibizumab (IVR) or triamcinolone acetonide (IVTA) or laser photocoagulation therapy (LPT) provided data on pre-treatment (baseline) and final outcome measures. Net changes and relative changes (percentage) were assessed by linear regression analyses.

KW - anti-VEGF treatments, corticosteroid treatments, diabetic macular oedema, laser photocoagulation

U2 - 10.1111/cxo.12393

DO - 10.1111/cxo.12393

M3 - Article

VL - 99

SP - 491

EP - 497

JO - Clinical and Experimental Optometry

JF - Clinical and Experimental Optometry

SN - 0816-4622

IS - 6

ER -